We examined whether [ 18 F]LBT-999 ((E)-N-(4-fluorobut-2-enyl)2β-carbomethoxy-3β-(4'-tolyl)nortropane) is an efficient positron emission tomography (PET) tracer for the quantification of the dopamine transporter (DAT) in the healthy rat brain. Methods: PET studies were performed using several experimental designs, i.e. test-retest, co-injection with different doses of unlabelled LBT, displacement with GBR12909 and pre-injection of amphetamine. Results: The uptake of [
Introduction
The dopamine transporter (DAT) is involved in a number of physiological and pathological processes in the brain. It is now recognized that in vivo exploration of this transporter by molecular single-photon emission computed tomography (SPECT) or positron emission tomography (PET) imaging can improve the early and/or differential diagnosis of Parkinson's disease (PD) [1, 2] and can also be useful in neuropsychiatric disorders such as schizophrenia [3] and attention deficit-hyperactivity disorders (ADHD) [4] . This in vivo exploratory approach requires the use of radioactive probes with properties allowing to specifically quantify the molecular target of interest in physiological and pathological conditions. To date several SPECT and PET tracers of the DAT are available [5] . Several [9] , and some of them are currently tested for potential clinical applications. Among the different exiting in vivo DAT tracers, it seems that PE2I has greater selectivity, in particular over the serotonin transporter (SERT) [10] . The fluorinated derivative of PE2I, (E)-N-(4-fluorobut-2-enyl)2β-carbomethoxy-3β-(4′-tolyl)nortropane or LBT-999 that we previously developed showed also very high selectivity for the DAT [11] and its labeled analog [ 18 F]LBT-999 has recently demonstrated its ability for in vivo quantification of the DAT in non-human primates [12] . The aim of the present study is to determine whether [ 18 
F]LBT-999
is an efficient tool for the quantification of DAT in the rat brain in vivo. Indeed, the development of PET systems adapted to small animals substantially increased during the last decade. Such technology is very useful for providing the proof of principle in the development of new imaging probes, for better understanding the pathophysiological mechanisms involved in human brain disorders and for validating new treatments in animal models. We characterized here in the healthy rat brain the reproducibility, reliability, and specificity of [ 18 ethanol. The formulation was completed by the addition of 3.5 mL of NaCl 0.9%. The preparation took 65 ± 5 minutes. Quality control was performed by HPLC (Alltima, C18, 250 × 4.6 mm, 5 μm column) using ammonium acetate 0.1 M/acetonitrile: 3/7. [ 18 F]LBT-999 was obtained with a radiochemical purity N 98% and with a mean specific activity of 109 ± 38 GBq/μmol.
Animals
All procedures were conducted in accordance with the requirements of the European Community Council Directive 2010/63/EU for the care of laboratory animals and with the authorization of the Regional Ethical Committee. A total of 36 male Wistar rats (2-monthsold; body weight of 300-350 g; CERJ Le Genest-St-Isle, France) were explored. They were housed in groups of 2 per cage in a temperature (21 ± 1°C) and humidity (55 ± 5%) controlled environment under a 12-hour light/dark cycle, with food and water available ad libitum.
PET acquisition and reconstruction
PET acquisitions were performed on a microPET eXplore VISTA-CT system (GE Healthcare, France) which has an effective axial/transaxial field of view (FOV) of 4.8/6.7 cm, a spatial resolution ≤2 mm, and a sensitivity of 2.5% in the whole FOV.
Animals were anesthetized using Aerrane (Baxter, France), at 4-5% in O 2 for induction and then 1.5-2% during the scan. Each rat was placed on a thermo-regulated bed (Minerve, France) in prone position with the head immobilized by 2 ear bars and a nose cone. The brain was positioned on the center of the FOV. Before PET acquisition, a 5-minutes computerized tomography X ray scan was acquired for attenuation correction. Animals received into a tail vein a bolus injection of 37 MBq/300 g body weight of [
18 F]LBT-999 in saline, corresponding to a mean dose of 1.25 nmol/kg. During PET acquisition, the respiratory rate and body temperature were monitored and kept as constant as possible. Each acquisition lasted between 50 and 70 minutes, depending on the experiment. For 50-minute acquisitions, list-mode scans were rebinned into 27 frames: 4 frames of 10-seconds followed by 4 of 20-seconds, 4 of 60-seconds, 14 of 180-seconds, and 1 of 120-seconds. For 70-minutes acquisitions, list-mode scans were rebinned into 29 frames: 4 frames of 10-seconds followed by 4 of 20-seconds, 4 of 60-seconds, 13 of 180-seconds, 3 of 360-seconds, and 1 of 420-seconds.
Each scan was corrected for randoms, scatter, and attenuation, and the images were reconstructed using a 2D OSEM algorithm (GE Healthcare, France) into voxels of 0.3875 × 0.3875 × 0.775 mm 3 .
Image analysis
All the dynamic PET images were co-registered into Paxinos coordinates by rigid transformations [14] . For each scan, the data were summed over the first 5 minutes after radiotracer injection to create a pseudo perfusion image. This image, which reflects the initial flow-dependent activity, was recorded with a 18 FDG template [15] using PMOD® (version 3.3, PMOD Technologies, Zurich, Switzerland, www.pmod.com) by maximizing normalized mutual information using Powell optimization. After checking for potential head movements, the transformation obtained by registering the pseudo perfusion image was used to register all frames of the corresponding dynamic sequence.
The regions of interest (ROIs) of the Schiffer template [15] corresponding to the striatum and cerebellum were eroded in 3D by 2 voxels to obtain regions less impacted by partial volume effect. The region of the substantia nigra/ventral tegmental area (SN/VTA) was manually drawn on the Schiffer magnetic resonance imaging template in Paxinos coordinates. These three regions were used to generate regional time-activity curves (TACs) on the co-registered images. In each region, the left and right sides were averaged.
Kinetics models
We determined the binding potential related to the nondisplaceable uptake (BP ND ), which is the concentration of specific binding at equilibrium compared to a reference concentration in a region without (or with negligible) specific binding [16] . The cerebellum was used as the reference region due to its very low DAT concentration. Five kinetic models based on the entire acquisition and that do not necessitate arterial sampling input function were considered as proposed by Elmenhorst et al. [17] : (i) Noninvasive Logan graphical analysis (Logan): the BP ND was calculated as the slope of a linear regression after reaching equilibrium [18] . A prerequisite is the calculation of the clearance rate k 2 ′ which was done using the SRTM method; (ii) simplified reference tissue model (SRTM): this model developed by Lammertsma et al. [19] was used here according to the method proposed by Gunn et al. [20] , by fitting basis functions calculated as the convolution of the reference time-activity curve (TAC) with decaying exponentials. Both BP ND and k 2 ′ estimations were considered for this study; (iii) two-step simplified reference tissue model (SRTM2): the SRTM2 model is similar to the SRTM model except that a global k2′ value is used for calculation, which reduces the effect of noise on BP ND parameter; (iv) multi-linear reference tissue model (MRTM): in this approach, both a receptor-rich and a receptor-poor regions are required to eliminate the necessity of an input function. Multi-linear regression is used to estimate the BP ND ; (v) Two-parameter simplified reference tissue model (MRTM2): similarly to the simplification of SRTM, the number of variables of MRTM is reduced by predetermination of a global parameter k 2 ′.
Simplified equilibrium analysis
The 5 kinetic models described in the previous section require long dynamic acquisition and dedicated softwares. Simple static measurements involving shorter acquisition protocols are of great interest to reduce the complexity of the dynamic data acquisition. Consequently, we studied a sixth method based on pseudo-equilibrium analysis that is only based on a 20-minutes window of the scans. When the radioligand concentration in the target region (C T ) is at equilibrium with the concentration in the non-displaceable compartment (C ND ), the rate of clearance is constant. Under this condition, the binding potential can be estimated as [16, 21] :
where the ratio C T /C ND is termed the distribution volume ratio (DVR). For evaluation of this simplified parameter, the average values from 30 to 50 minutes (t′) in the target ROI and in the cerebellum were used in all studies except displacement study, as these ratios were approximately constant over this time interval. For the displacement study, specific time intervals before and after GBR12909 injection were defined as detailed in section 2.9.
Test-retest experiment
Ten animals were used, each rat being scanned twice within a maximal interval of 2 weeks (body weight, 324 ± 35 g at first and 346 ± 36 g at second scan) at the same time of the day (between 2 and 4-p.m.). [ 18 F]LBT-999 (37 MBq/300 g body weight in saline) was administered as a bolus injection into the tail vein. For this experiment, the mean specific activity was 101 ± 27 GBq/μmol. Average BP ND were calculated in each ROI for scan1 (n = 10) and scan 2 (n = 10) according to the six models (Logan, SRTM, SRTM2, MRTM, MRTM2 and DVR-1).
Transporter occupancy
As detailed by Hume and colleagues [30] , occupancy at binding sites can be defined as:
Considering the ligand dose to be related to the radioactivity injected, its specific activity and the animal weight, the following equation is derived:
It can be rearranged the following way: mixture of labeled and unlabeled LBT-999 was injected as a bolus at the dose of 37 MBq/300 g body weight in saline into the tail vein of three animals per dose of unlabeled LBT-999. The BP ND obtained depending on the LBT-999 concentrations were plotted and the ED50 was derived from the best fit of the data obtained using GraphPad Prism (GraphPad Software, CA).
Displacement study
Five rats were used, each receiving 1 mg/kg GBR12909 (Tocris bioscience, R&D System, France) as a bolus injection into the tail vein at 35 minutes post [ 18 F]LBT-999 bolus injection at the dose of 37 MBq/ 300 g body weight in saline into the tail vein. For this study, the PET scan was recorded during 70 minutes in order to reach the basal accumulation value. The time intervals used for DVR-1 calculations were defined as follows: between 21 and 36 min (baseline) and between 57 and 70 minutes (with GBR12909) after the radiotracer injection.
Amphetamine study
In order to evaluate the sensitivity of [ 18 F]LBT-999 binding to changes in the concentration of endogenous dopamine, 6 rats were scanned twice within a maximal interval of 4 days, the first scan in basal condition and the second performed 20 minutes after an intravenous injection of amphetamine 2 mg/kg (Sigma-Aldrich, France). The time intervals to estimate BP ND were as described for the test-retest study (see 2.5 for the kinetics models and 2.6 for the equilibrium analysis).
Statistical analyses
For the test-retest experiments, reliability of the BP ND parameters was assessed by computation of 2 characteristic criteria for each of the 6 kinetic models:
• The reproducibility of the PET quantification was assessed by test-retest variability (VAR), which was calculated as the percentage of test-retest difference:
where scan1 and scan2 represent the BP ND values from the first and second scans, respectively.
• The test-retest reliability was assessed using the intraclass correlation coefficient (ICC), calculated by one way ANOVA as:
where MSBS and MSWS are the mean sum of squares between and within subjects, respectively. In all experiments, the P-values for group differences were obtained using Student's t test, and they were considered statistically significant at P b 0.05. Values are presented as the mean ± standard error of the mean. The relationships between the BP ND values derived from the Logan, SRTM, SRTM2, MRTM and MRTM2 models, and the DVR-1 values from the simplified quantification protocol were assessed using the square of the Pearson's product moment correlation coefficient (R 2 ).
Results

Kinetics analysis
Images at different times after injection of [ 18 F]LBT-999 showed a progressive accumulation of radioactivity in the striatum (Fig. 1A) . Time-activity curves are presented in Fig. 1B . After intravenous bolus injection of the tracer, a rapid uptake was observed in the 3 ROIs examined (i.e., the striatum, SN/VTA and cerebellum). In the cerebellum, the uptake decreased sharply and remained low and stable from 20 minutes post-injection (p.i.). By contrast, the uptake remained high and stable in the striatum, with a stable standardized uptake value (SUV) around 5 from 5 to 50 minutes p.i. In the SN/VTA, the uptake also decreased progressively but slower than in the cerebellum, reaching a stable low value around 35-40 minutes p.i.
Test-retest study
The test-retest variability and reliability values of [ 18 F]LBT-999 binding were determined from 10 healthy rats (Fig. 1B) . The BP ND varied between 4.33 ± 0.28 and 5.37 ± 0.33 in the striatum and between 0.16 ± 0.05 and 0.79 ± 0.12 in the SN/VTA, considering the 6 different quantification models used (Logan, SMTR, SMTR2, MRTM, MRTM2, and DVR-1) ( Table 1 ). The variability in the striatum was low whatever the method used for the BP ND determination, i.e., between 8 ± 1 and 14 ± 2. This variability was obviously higher in the SN/ VTA, i.e., between 11 ± 2 and 58 ± 10, according to the method. The test-retest reliability was high in the striatum (mean ICC of 0.90 to 0.72) and lower in the SN/VTA (0.55 to 0.07). It can be noted that the variability and reliability of the BP ND determination were better in the striatum than in the SN/VTA whatever the quantification method used, probably due to the small size of the SN/VTA area. In the striatum, similar variability and reliability were observed for 5 of the 6 methods used (Logan, SRTM, SRTM2, MRTM2 and DVR-1).
In the striatum, the DVR-1 method consistently overestimated BP ND estimates compared with the Logan (overestimation of 23%, P = 0.002), SRTM (15%, P = 0.03), SRTM2 (16%, P = 0.02), MRTM (12%, P = 0.05), and MRTM2 (16%, P = 0.02) methods. However, the (Table 2 ). Thus we used the DVR-1 method for the estimation of transporter occupancy and displacement study.
Transporter occupancy
The co-injection of increasing doses of unlabeled LBT-999 induced a reduction in the BP ND of 12% and 54% for administration of 0.1 and 0.3 mg/kg, respectively, and a decrease in BP ND of 80% in the presence [15] corresponding to the striatum and cerebellum were eroded in 3D by 2 voxels to obtain regions less impacted by partial volume effect. The region of SN/VTA was manually drawn on the Schiffer MRI template in Paxinos coordinates [14] . These three regions were used to generate regional TACs on the co-registered images. In each region, the left and right sides were averaged (n = 10). Results are expressed as mean ± SEM; n = 10. BP ND , binding potential non displaceable; % Var., % variability; ICC, intraclass correlation coefficient (reliability). 
. Representative coronal [ 18 F]LBT-999 images at different times after bolus injection (A). Mean time-activity curves in the striatum, SN/VTA, and cerebellum in the test-retest experiment (B). The regions of interest of the Schiffer template
Displacement study
As seen in Fig. 3A , the intravenous injection of 1 mg/kg GBR12909 induced a rapid and strong decrease in the striatal accumulation of [ (Fig. 3B) .
Amphetamine study
Images at different times after injection of [
18 F]LBT-999 are shown for an animal without amphetamine pre-injection (baseline, top) and with pre-injection (bottom) (Fig. 4A ). The TACs of [
18 F]LBT-999 in animals pre-injected with amphetamine showed that this treatment induced a marked decrease in the radiotracer binding in the striatum (P = 0.005, t test) and SN/VTA (p = 0.001, t test), whereas the cerebellum uptake was similar in both conditions (P = 0.36) (Fig. 4B ). Of note, the peak accumulation of the tracer was higher in the striatum of amphetamine-injected rats than in non-injected rats during the first 10 minutes p.i. (Fig. 4A and B) .
As shown in Table 3 , the BP ND was reduced under amphetamine administration by 45-59% in the striatum and by 44-88% in the SN/ VTA, depending on the method used (Logan, SRTM, SRTM2, MRTM, MRTM2, or DVR-1).
Discussion
This study examined the quantification of in vivo [
18 F]LBT-999 binding to the DAT in the healthy rat brain. As expected, the intensity of regional brain uptake of this radiotracer over time was in agreement with the known DAT density, i.e., striatumNNSN/ VTANcerebellum. The cerebellum was used as the nonspecific binding brain region and we further evaluated the applicability of widely used reference tissue methods to estimate the BP ND of [
18 F]LBT-999 using various methods such as Logan, SRTM, SRTM2, MRTM, MRTM2, and DVR-1.
In the striatum, the estimated BP ND (test experiment) was comprised between 5.37 (DVR-1) and 4.39 (Logan) [26] and [ 11 C]methylphenidate in mice [21] .
In our experiments, the DVR-1 method overestimated BP ND values by 12-23% compared with other quantification methods. Consistent with the literature [21] , this bias originates from the plasma clearance rate and relative tissue eigenvalue that can significantly alter the apparent volume of distribution [27] . While an overestimation was observed, the simplified quantification based on target ROI to cerebellum ratio at equilibrium (DVR-1) was highly correlated with the 5 studied kinetic models. The present data suggest that short imaging times (10-20 minutes) for imaging conducted less than 30 minutes after the administration of [
18 F]LBT-999 are feasible for small animals. High reproducibility and reliability are prerequisites for the use of a PET tracer in the evaluation of DAT in pharmacological challenges and/ or animal models of brain disorders. In this study, the non-invasive DAT quantification using [
18 F]LBT-999 in the striatum assessed by the BP ND was reproducible with low variability ranging from 8 to 14%, depending on the model used. The reliability of DAT quantification was high in this region, reaching for example an ICC of 0.90 using the SRTM2 model. In the SN/VTA where the dopaminergic cell bodies are localized, the variability was much higher (26-58%) and the reliability was lower than in the striatum, probably due to the small size of this brain region that renders it more sensitive to misalignment and more affected by partial volume effects. In both regions, lowest reproducibility and reliability were obtained for the MRTM model, which is known to be noisier due to the use of late data only. The variability found here in the striatum was comparable to those reported in several test-retest studies in rodents for other PET tracers of the dopaminergic system such as the DAT tracers [ [29] ). The selectivity of in vivo binding of LBT-999 to the DAT versus the serotonergic and noradrenergic transporters in the rat brain had already been assessed [11] . The present data confirmed this high selectivity as demonstrated by rapid and strong decrease in the striatal accumulation of the tracer after inhibition of the binding by acute administration of GBR12909.
An interesting feature of [ 18 F]LBT-999 is its ED 50 of 0.02 mg/kg. In fact, such a value implies that the maximum occupancy of the tracer on the DAT is very close to occupancies required for being at tracer dose [30] . Therefore, the use of [ 18 F]LBT-999 in our conditions satisfies the radiotracer kinetic modeling assumptions despite the pharmacological constraints related to small animal imaging.
To complete the in vivo characterization of [
18 F]LBT-999 binding, we performed a pharmacological test with amphetamine in order to assess its sensitivity to variations of synaptic dopamine levels. Amphetamine is a substrate for DAT that competitively inhibits dopamine (DA) uptake [31] . In addition, a number of in vitro studies showed that amphetamine is also able to induce DAT internalization, associated with a reduction in extracellular DA uptake [32] . It seems that in vivo amphetamine exposure also reduces DAT activity even if this reduction is not related to change in DAT cellular localization [33] . Based on microdialysis studies [34, 35] , it can be extrapolated that the dose of amphetamine we used induced a 2-to 3-fold increase in the striatal endogenous DA level, and was accompanied with a reduction in DAT activity. We observed that an acute pre-injection of fallypride [37] , and was in accordance to that already shown for the F]LBT-999 has been described in the rat brain although their specific binding to the DAT in the striatum could not be ascertained [41] . Therefore, it cannot be excluded that the presence of these metabolites could interfere with the absolute quantification of DAT. However, considering that in rats the tracer will most of the time be used in different experimental groups including a control group, this aspect does not represent a major drawback. It can be expected that [ 18 F]LBT-999 will be now used in numerous rodent models of brain disorders to examine and quantify the DAT, allowing to further study and develop treatments for neurodegenerative and neuropsychiatric diseases. 
